28 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
believe the benefits described above are necessary and appropriate to provide a competitive compensation package to our Named Executive Officers.
Table
6-K
EX-99.2
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
of uterine fibroids. The NDA submission includes the positive PRIMROSE 1 and PRIMROSE 2 full data package including week 52 data and post treatment follow-up
424B7
1x6kkra9i hf
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
g62mhhc
17 Feb 22
Shelf registration (foreign)
4:14pm
424B7
msxy46u aw6
23 Nov 21
Prospectus with selling stockholder info
4:06pm
F-3
ds1pbghoacq46d sms4
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
h19lx9
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
pac87kk8rt5hl r9ox
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
brchdn2 3l1phpdbwbma
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
n9gxf4 x3v1o
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
gmx2y9pdg0cqd6tqvqx7
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-99.2
egyl5l i5fcfmn0npl3
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-1.1
6r9y5 9pnb8
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am